A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B

Archives of Internal Medicine

Volumn 166, Issue 1, 2006, Pages 49-56

  Lim, Seng Gee ^a   Ng, Tay Meng ^b   Kung, Nelson ^d   Krastev, Zahary ^e   Volfova, Miroslava ^f   Husa, Petr ^g   Lee, Samuel S ^h   Chan, Sing ⁱ   Shiffman, Mitchell L ^j   Washington, Mary Kay ^k   Rigney, Amy ^l   Anderson, Jane ^l   Mondou, Elsa ^l   Snow, Andrea ^l   Sorbel, Jeff ^l   Guan, Richard ^c   Rousseau, Franck ^l  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

^c MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^d UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^e UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^f UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^g UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^j VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l GILEAD SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; AMYLASE; BILIRUBIN; CREATINE KINASE; EMTRICITABINE; GLUCOSE; HEPATITIS B(E) ANTIGEN; PLACEBO; POTASSIUM; SODIUM; TRIACYLGLYCEROL LIPASE; VIRUS DNA;

ABDOMINAL PAIN; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EUROPE; FATIGUE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLUENZA; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION; NORTH AMERICA; PAIN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEROCONVERSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS RESISTANCE;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY, NEEDLE; DEOXYCYTIDINE; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; PLACEBO EFFECT; TREATMENT OUTCOME; VIRAL LOAD;

EID: 30344457555     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.1.49     Document Type: Article

References (33)

1. Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39:S50-S58.
2. Robins GW, Scott LJ, Keating GM. Peginterferon-α-2a (40kD) a review of its use in the management of patients with chronic hepatitis B. Drugs. 2005;65:809-825.
3. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617-624.
4. Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol. 2003;13:255-272.
5. Conjeevaram HS, Lok AS-F. Management of chronic hepatitis B. J Hepatol. 2003;38:S90-S103.
6. Keeffe EB, Dieterich DT, Han S-HB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87-106.
7. Baraclude [US package insert]. Wallingford, Conn: Bristol-Myers Squibb Co; March 2005.
8. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350:1118-1129.
9. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). Presented at: 40th Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2005; Paris, France.
10. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992;36:2686-2692.
11. Delaney WE IV, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48:3702-3710.
12. Gish RG, Leung NY, Wright TL, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother. 2002;46:1734-1740.
13. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol. 2005;43:60-66.
14. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31:241-246.
15. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
16. AIDS Clinical Trial Group. Division of AIDS Table for Grading Severity of Adult Adverse Experiences, 1996. Rockville, Md: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
17. Applied Biosystems. ABI Prism 3100 Genetic Analyzers Users Guide. Foster City, Calif: Applied Biosystems; 2003.
18. Ladner S, Otto M, Barker C, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother. 1997;41:1715-1720.
19. Ladner SK, Miller TJ, King RW. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother. 1998;42:2128-2131.
20. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology. 2002;36:710-722.
21. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. Am Stat Assn J. 1963;58:690-700.
22. van Elteren PH. On the combination of independent two sample tests of Wilcoxon. Bull Int Stat Inst. 1958;37:351-361.
23. Marcellin P, Chang T-T, Lim SG, et al. Adefovir for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
24. Hadziyannis SJ, Tassopoulos N, Heathcote EJ, et al. Adefovir for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.
25. Shouval D, Lai C-L, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027. Presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases; October 29-November 2, 2004; Boston, Mass.
26. Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naïve patients. Presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases; October 29-November 2, 2004; Boston, Mass.
27. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-68.
28. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
29. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51:597-599.
30. Honkoop P, De Man RA, Niesters HGM, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000;32:635-639.
31. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225-1241.
32. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302-1306.
33. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185-1192.